Cargando…
Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure
The present study aimed to compare the short-term prognostic performance of a series of model for end-stage liver disease (MELD) and respective delta (Δ) scores scoring systems in a population with acute-on-chronic hepatitis B liver failure (ACHBLF), and to investigate the potential effects from ant...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020485/ https://www.ncbi.nlm.nih.gov/pubmed/24573151 http://dx.doi.org/10.3892/mmr.2014.1983 |
_version_ | 1782316075515379712 |
---|---|
author | XUN, YUN-HAO SHI, JUN-PING LI, CHUN-QING LI, DAN SHI, WEI-ZHEN PAN, QING-CHUN GUO, JIAN-CHUN ZANG, GUO-QING |
author_facet | XUN, YUN-HAO SHI, JUN-PING LI, CHUN-QING LI, DAN SHI, WEI-ZHEN PAN, QING-CHUN GUO, JIAN-CHUN ZANG, GUO-QING |
author_sort | XUN, YUN-HAO |
collection | PubMed |
description | The present study aimed to compare the short-term prognostic performance of a series of model for end-stage liver disease (MELD) and respective delta (Δ) scores scoring systems in a population with acute-on-chronic hepatitis B liver failure (ACHBLF), and to investigate the potential effects from antivirals. A total of 77 patients with ACHBLF of mean age 46 years, 82% male, with 58.4% receiving antivirals, were recruited for this study. The Δ scores for MELDs were defined as the changes one week after admission. Thirty-eight (49%) patients (22 treated with antivirals) died within three months. The mean MELD and ΔMELD scores of the survival group were 19.5±4.4 and 0.2±3.7 respectively, and those of the mortality group were 23.5±5.5 and 7.9±6, respectively. The area under the receiver operating characteristic curve (AUC) for MELD, integrated MELD (iMELD), MELD with the addition of serum sodium (MELD-Na), updated MELD (upMELD), MELD excluding the international normalized ratio (INR; MELD-XI), United Kingdom MELD (UKMELD) and their Δ scores were 0.72, 0.81, 0.77, 0.69, 0.65, 0.77 and 0.86, 0.83, 0.83, 0.82, 0.79 and 0.79, respectively. iMELD and MELD-Na significantly improved the accuracy of MELD (P<0.05). A cut-off value of 41.5 for the iMELD score can prognose 71% of mortalities with a specificity of 85%. In each pair of models, the Δ score was superior to its counterpart, particularly when applied to patients with MELD ≤30. Decreased accuracy was observed for all models in the subset of patients treated with antivirals, although their baseline characteristics were comparable to those of untreated patients, while iMELD, MELD-Na and respective Δ models remained superior with regard to the predictability. The iMELD and MELD-Na models predicted three-month mortality more accurately, while the Δ models were superior to their counterparts when MELD ≤30; however, their performance was altered by antivirals, and thus requires optimization. |
format | Online Article Text |
id | pubmed-4020485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-40204852014-05-14 Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure XUN, YUN-HAO SHI, JUN-PING LI, CHUN-QING LI, DAN SHI, WEI-ZHEN PAN, QING-CHUN GUO, JIAN-CHUN ZANG, GUO-QING Mol Med Rep Articles The present study aimed to compare the short-term prognostic performance of a series of model for end-stage liver disease (MELD) and respective delta (Δ) scores scoring systems in a population with acute-on-chronic hepatitis B liver failure (ACHBLF), and to investigate the potential effects from antivirals. A total of 77 patients with ACHBLF of mean age 46 years, 82% male, with 58.4% receiving antivirals, were recruited for this study. The Δ scores for MELDs were defined as the changes one week after admission. Thirty-eight (49%) patients (22 treated with antivirals) died within three months. The mean MELD and ΔMELD scores of the survival group were 19.5±4.4 and 0.2±3.7 respectively, and those of the mortality group were 23.5±5.5 and 7.9±6, respectively. The area under the receiver operating characteristic curve (AUC) for MELD, integrated MELD (iMELD), MELD with the addition of serum sodium (MELD-Na), updated MELD (upMELD), MELD excluding the international normalized ratio (INR; MELD-XI), United Kingdom MELD (UKMELD) and their Δ scores were 0.72, 0.81, 0.77, 0.69, 0.65, 0.77 and 0.86, 0.83, 0.83, 0.82, 0.79 and 0.79, respectively. iMELD and MELD-Na significantly improved the accuracy of MELD (P<0.05). A cut-off value of 41.5 for the iMELD score can prognose 71% of mortalities with a specificity of 85%. In each pair of models, the Δ score was superior to its counterpart, particularly when applied to patients with MELD ≤30. Decreased accuracy was observed for all models in the subset of patients treated with antivirals, although their baseline characteristics were comparable to those of untreated patients, while iMELD, MELD-Na and respective Δ models remained superior with regard to the predictability. The iMELD and MELD-Na models predicted three-month mortality more accurately, while the Δ models were superior to their counterparts when MELD ≤30; however, their performance was altered by antivirals, and thus requires optimization. D.A. Spandidos 2014-05 2014-02-25 /pmc/articles/PMC4020485/ /pubmed/24573151 http://dx.doi.org/10.3892/mmr.2014.1983 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles XUN, YUN-HAO SHI, JUN-PING LI, CHUN-QING LI, DAN SHI, WEI-ZHEN PAN, QING-CHUN GUO, JIAN-CHUN ZANG, GUO-QING Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure |
title | Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure |
title_full | Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure |
title_fullStr | Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure |
title_full_unstemmed | Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure |
title_short | Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure |
title_sort | prognostic performance of a series of model for end-stage liver disease and respective δ scores in patients with hepatitis b acute-on-chronic liver failure |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020485/ https://www.ncbi.nlm.nih.gov/pubmed/24573151 http://dx.doi.org/10.3892/mmr.2014.1983 |
work_keys_str_mv | AT xunyunhao prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure AT shijunping prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure AT lichunqing prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure AT lidan prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure AT shiweizhen prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure AT panqingchun prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure AT guojianchun prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure AT zangguoqing prognosticperformanceofaseriesofmodelforendstageliverdiseaseandrespectivedscoresinpatientswithhepatitisbacuteonchronicliverfailure |